-
In 2023, another Class 1 new drug was approved, and the NMPA conditionally approved the marketing of mobosetinib succinate capsules
Time of Update: 2023-02-01
The launch of this drug provides a new treatment option for patients with advanced non-small cell lung cancer who carry EGFR exon 20 insertion mutation positive.
The launch of this drug provides a new treatment option for patients with advanced non-small cell lung cancer who carry EGFR exon 20 insertion mutation positive.
-
The State Food and Drug Administration approved the marketing of torudibin lafaxine hydrochloride sustained-release tablets
Time of Update: 2022-11-14
Source/ NMPA website Recently, the State Medical Products Administration approved the marketing of the Class 1 innovative drug Torudiven Lafaxine hydrochloride sustained-release tablets (trade name: Ruoxinlin) declared by Shandong Luye Pharmaceutical Co.
-
In August, a large number of pharmaceutical companies announced that their products passed the consistency evaluation. Northeast Pharmaceuticals, Lianhuan Pharmaceuticals, etc
Time of Update: 2022-08-15
Bihuan Pharmaceutical: Drotaverine Hydrochloride Injection was over-reviewed and won the first one On August 5, Bihuan Pharmaceutical announced that the company's Drotaverine Hydrochloride Injection has recently passed the quality and efficacy consistency evaluation of generic drugs .
-
New progress in drug research on fish enterohepatic inflammation
Time of Update: 2022-05-17
According to the above drug prediction results of fish enterohepatic inflammation, sea buckthorn was added to the feed to evaluate its anti-enterohepatic inflammation effect in the zebrafish foodborne enteritis model ( SBMIE ) model (patent authorized), Using immune gene expression analysis, immune cell imaging, pathological and growth evaluation, multi-omics analysis (transcriptome and microbiome) and other methods, the molecular immune mechanism of sea buckthorn against intestinal liver inflammation was revealed .
-
There is a large unmet clinical demand for rare disease drugs, and multinational pharmaceutical companies continue to enter the market
Time of Update: 2022-05-14
Bristol-Myers Squibb, as an early multinational pharmaceutical company in the field of rare diseases, has also made continuous efforts in the research and development of rare diseases in recent years .
-
The clinical trial application of ASK0912 for injection, a subsidiary of Osaikang, was accepted
Time of Update: 2022-04-27
On March 16, 2022, Osaikang issued an announcement stating that Jiangsu Osaikang Injection ASK0912, a wholly-owned subsidiary of the company, recently received the "Notice of Acceptance" for the application for new drug clinical trials issued by the NMPA .
-
Two articles by Zhejiang University scholar PNAS and others: Revealing a new mechanism for the division of cellular DNA polymerase functions
Time of Update: 2022-04-26
On March 15 , 2022 , PNAS , the Proceedings of the National Academy of Sciences, published online the research paper Global genomic instability caused by reduced expression of DNA polymerase ε in yeast in which Zhang Ke , a distinguished researcher at the Institute of Microbiology, School of Life Sciences, Zhejiang University, is the first author .
-
Breakthrough therapy drugs ushered in major benefits, and innovative drugs from multi-pharmaceutical companies such as Novartis were included
Time of Update: 2022-04-25
This procedure does not require applicants to apply, and the innovative drug varieties included in the breakthrough therapy drug procedure can automatically carry out follow-up communication and review and approval according to this procedure .
-
A large number of drugs for the treatment of advanced solid tumors have been approved for clinical use, involving Hengrui, Henlius, etc
Time of Update: 2022-04-15
HLX301 Fosun Pharma announced that recently, the application for clinical trials of HLX301 (recombinant human anti-PD-L1 and anti-TIGIT bispecific antibody injection) of Henlius, a holding subsidiary of the company, for the treatment of advanced tumors has been approved by the State Food and Drug Administration.
-
What's behind the NMPA's emergency approval of Pfizer's new coronavirus drug import
Time of Update: 2022-03-07
On February 12, 2022, the State Food and Drug Administration announced that Pfizer's new coronavirus treatment drug nematevir tablet/ritonavir tablet combination package import registration has been approved with emergency conditions .
-
Alis Medical's third-generation EGFR-TKI plans to be included in breakthrough treatment products
Time of Update: 2022-01-14
ArticleMedicine GuanlanOn November 23, the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that the third-generation EGFR-TKI vometinib mesylate tablets of Allis Pharmaceuticals will be included in the breakthrough treatment product, and the proposed indication is : First-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) replacement mutation .
-
Professor Lu Ming: Sofantinib combined with teriprizumab in the treatment of neuroendocrine cancer sings on the international stage and brings more hope to patients
Time of Update: 2021-12-06
The recent 2021 North American Society of Neuroendocrine Oncology (NANETS) annual meeting announced the latest data from the Phase II clinical study of sofatinib combined with teriprizumab in the treatment of advanced neuroendocrine cancer that failed first-line chemotherapy .
-
Sanofi clopidogrel aspirin tablets approved in China
Time of Update: 2021-10-21
Public information shows that this is an anti-platelet single-tablet compound (SPC), which is suitable for preventing atherosclerotic thrombosis in adult patients with acute coronary syndrome who have taken clopidogrel and aspirin at the same time .
Chinese expert consensus on antiplatelet therapy of clopidogrel/aspirin single-tablet compound preparation[J].
-
6 substances including MAPA are listed in the management of precursor chemicals
Time of Update: 2021-09-12
According to the content of the announcement, the production, operation, purchase, transportation and import and export activities of six substances shall implement the relevant regulations on non-drug precursor chemicals .
-
What kind of innovative tumor drugs do patients need
Time of Update: 2021-07-30
"In early July, the Drug Evaluation Center of the State Food and Drug Administration issued the "Guiding Principles for Clinical Research and Development of Anti-tumor Drugs Oriented by Clinical Value"Once this news was released, it ushered in a continuous decline in pharmaceutical-related stocks .
